Evidence map›Paper›PMID 35185643›Full record

ReviewFrontiers in psychiatry2021

Assessment and Treatment of Negative Symptoms in Schizophrenia-A Regional Perspective.

Istvan Bitter, Pavel Mohr, Natalia Raspopova, Agata Szulc, Jerzy Samochowiec, Ioana Valentina Micluia, Oleg Skugarevsky, Róbert Herold, Alma Mihaljevic-Peles, Nino Okribelashvili and 9 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 19 institutions in 17 countries.

Istvan BitterDepartment of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
Pavel MohrClinical Center, National Institute of Mental Health, Klecany, Czechia.
Natalia RaspopovaDepartment of Psychiatry, Narcology and Neurology of Kazakh-Russian Medical University, Almaty, Kazakhstan.
Agata SzulcDepartment of Psychiatry, Medical University of Warsaw, Warsaw, Poland.
Jerzy SamochowiecDepartment of Psychiatry, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Ioana Valentina MicluiaDiscipline of Psychiatry, Department of Neurosciences, University of Medicine and Pharmacy, Iuliu Haieganu, Cluj-Napoca, Romania.
Oleg SkugarevskyDepartment of Psychiatry & Medical Psychology, Belarusian State Medical University, Minsk, Belarus.
Róbert HeroldDepartment of Psychiatry and Psychotherapy, Medical School, University of Pécs, Pécs, Hungary.
Alma Mihaljevic-PelesClinical Hospital Centre Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.
Nino OkribelashviliDepartment of Psychiatry and Medical Psychology, Tbilisi State University, Tbilisi, Georgia.
Jozef DragašekFirst Department of Psychiatry, University of P. J. Safarik, Medical Faculty and University Hospital of L. Pasteur, Kosice, Slovakia.
Virginija AdomaitieneDepartment of Psychiatry, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Elmars RancansDepartment of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.
Jana ChihaiMedical Psychology and Narcology Department, State Medical and Pharmaceutical University Nicolae Testemitanu, Chisinau, Moldova.
Natalia MarutaDepartment of Borderline Psychiatry, Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Science of Ukraine, Kharkiv, Ukraine.
Nadja P MarićFaculty of Medicine University of Belgrade & Institute of Mental Health, Belgrade, Serbia.
Vihra MilanovaPsychiatric Clinic, University Hospital "Alexandrovska", Sofia, Bulgaria.
Rok TavčarUniversity Psychiatric Clinic Ljubljana and School of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Sergey MosolovDepartment for Therapy of Mental Disorders, Moscow Research Institute of Psychiatry, Moscow, Russia.
Alexandrovska Hospital · BGBelarusian State Medical University · BYInstitute of Neurology, Psychiatry and Narcology · UAIuliu Hațieganu University of Medicine and Pharmacy · ROKazakh Institute of Oncology and Radiology · KZLithuanian University of Health Sciences · LTMedical University of Warsaw · PLNational Institute of Mental Health · CZNicolae Testemițanu State University of Medicine and Pharmacy · MDPomeranian Medical University · PLRiga Stradiņš University · LVRussian Medical Academy of Continuous Professional Education · RUSemmelweis University · HUTbilisi State Medical University · GEUniversity of Belgrade · RSUniversity of Pavol Jozef Šafárik · SKUniversity of Pecs · HUUniversity of Zagreb · HRUniversity Psychiatric Hospital · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinicians and researchers consider that there are a variety of symptoms that constitute negative symptoms in schizophrenia, and they may use different definitions for the same symptoms. These differences are also reflected in a variety of negative symptom rating scales. Both research and clinical work are negatively affected by the lack of consensus regarding the symptoms that constitute negative symptoms in schizophrenia. Leading research groups have investigated ways to reduce heterogeneity in the domain of negative symptoms in schizophrenia; however, little attention has been paid to regional differences in the concepts of negative symptoms in schizophrenia. The objective of this review was to collect and summarize information about the assessment and treatment of negative symptoms of schizophrenia in Central and Eastern Europe (CEE). Nineteen experts from 17 countries in CEE participated in this project. The participants collected information about their countries, including the following: (1) the most important publications about negative symptoms in schizophrenia (irrespective of the time of their publication); (2) the most frequently used negative symptom of schizophrenia in clinical practice; (3) definitions of frequently used negative symptoms; and (4) treatment of negative symptoms in schizophrenia. The participating experts/countries most frequently reported the following five negative symptoms: avolition, blunted affect, alogia, asociality, and anhedonia. Several experts also considered other symptoms as belonging to the negative symptom domain, such as a decrease in energy level and changes in personality. The importance of evaluating the long-term course and the relationship between negative symptoms and other symptom domains was also noted. No noticeable differences were reported in the treatment of negative symptoms compared to currently published guidelines and algorithms. The most frequently reported negative symptoms included those defined by the NIMH-MATRICS consensus statement on negative symptoms and recently endorsed in a guidance paper of the European Psychiatric Association. The main differences in the concepts, names, and definitions of primary negative symptoms, especially those related to personality changes, and to the evaluation of the long-term course and relationship between different symptom domains in CEE compared to the current English language literature deserve the attention of psychiatrists and other professionals in this field.

Indexed as

assessmentCentral and Eastern Europenegative symptomspersonalityreviewschizophreniatreatment

Identifiers

PMID35185643
PMCPMC8855151
OpenAlexW4210334040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.